الفهرس 
Nephrottiic SyndromeOnly 14 pages are availabe for public view
 |  | from | 99 |  |  |
| | | from | 99 | | |
Abstract
This study aims to evaluation of urinary Alpha 1 beta glycoproteins in urine of patients with childhood nephrotic syndrome.
It was conducted on a group of 75 patients with various types of childhood nephrotic syndrome clinically and laboratory diagnosed following up in the Pediatric Nephrology Clinic Children’s Hospital, Ain Shams University diagnosed for at least 6 months including patients in remission and relapse and 16 sex and age matched healthy children as a control.
52 (69.3%) of the studied cases were males and 23 (30.7%) were females with mean age of 8.23±2.4 while 11 (69%) of the studied control were males while 5 (31%) were females with mean age of 7.1±2.05.
Detailed history was taken from all patients and careful examination was done.
We did some investigations for all patients as complete urine analysis, Urine protein/ creatinine ratio in case of proteinuria, Renal function to exclude patients with renal impairment.
Measurement of Alpha 1-B glycoprotein in urine using ELISA kits was done.
The results of the study revealed that:
Male patients (69.3%) with nephrotic syndrome were predominant than females (30.7%).
The mean disease duration was 4.2±1.6years, with infrequent relapse in 82.7% of the studied cases, Frequent relapses in 2.6% of cases and steroid resistance in 14.7%.
45.3% of the studied cases had hypertension, and 14.7% of the studied cases had cushenoid facies.
82.8% of the studied cases are treated by prednisone, while 17.2% of them treated by combined treatment.
A1BG was measured in all the study groups and it was highly significantly higher in cases (patients with nephrotic syndrome) compared to control group. Furthermore the urinary levels of A1BG were highly significantly higher in steroid resistant nephrotic syndrome patients in comparison to steroid sensitive patients
On the other hand there was no significant difference in A1BG between cases as regards; proteinuria, blood pressure and sex.
In conclusion, A1BG represents a Non-invasive biomarker that could predict steroid responsiveness. It can differentiate steroid resistance in a subset of patients with nephrotic syndrome. So it can help patients to avoid unnecessary exposure to high-dose corticosteroids and help to tailor treatments with alternative drugs that are more likely to be beneficial for steroid-resistant patients.